- Who are we?
We are an international team of enthusiastic professionals devoted to developing the best bio-sensing solutions for people’s wellbeing. We aspire to help anyone to prevent life-threatening diseases with the most effective screening tools.
- What is our core technology?
We have developed a unique disease-risk-assessment platform able to collect blood micro-samples and analyze them without nucleotide purification to detect DNA/RNA biomarkers associated with life-threatening diseases. Currently, we are working on a colorectal cancer application.
- What is our product portfolio?
Our platform is composed of three main products: 1) an automated blood micro-sampling device (HaiimTM), 2) a qPCR-based disease-risk-assessment device (eGGiTM) along with reagent kits for specific diseases, 3) Winnoz AITM for estimation of disease risk.
- What is the target audience for our products?
HaiimTM has been categorized as a medical device class I by the Taiwanese Food and Drug Administration (TFDA). Currently, it can be used by professionals who are authorized by the local law to do blood sampling. Nevertheless, we are working closely with regulatory agencies to simplify our HaiimTM device for anyone to be able to collect blood micro-samples at homes and anywhere.
eGGiTM has two versions, for research-use-only (RUO) and clinical use (IVD). The former one does not need to be cleared by regulatory agencies. Therefore, it will be launched to market very soon.
- Who are our main customers?
Currently, HaiimTM’s main customers are hospitals, clinics, healthcare centers, screening centers, and clinical laboratories or similar entities that have the need to collect blood microsamples in a more pleasant, more efficient and safer way. We expect to serve patients in a short future.
eGGiTM’s main customers are clinical and non-clinical laboratories that need to do molecular test on-site and rapidly using novel top-notch but cost-effective technology.
- What is our business model?
Currently, we follow a B2B/B2B2C model. Nevertheless, we expect to serve patients directly in a short future, turning into a B2C model.